专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060210960A1 Method for processing and preserving collagen-based tissues for transplantation 审中-公开
公开(公告)号：US20060210960A1
公开(公告)日：2006-09-21
申请号：US11177167
申请日：2005-07-07
申请人： Stephen Livesey , Anthony Del Campo , Abhijit Nag , Ken Nichols , Edward Griffey , Christopher Coleman
发明人： Stephen Livesey , Anthony Del Campo , Abhijit Nag , Ken Nichols , Edward Griffey , Christopher Coleman
IPC分类号： A01N1/02 , C12N5/08
CPC分类号： A61L27/3683 , A01N1/00 , A01N1/02 , A01N1/0221 , A01N1/0231 , A61K35/18 , A61K39/12 , A61K39/13 , A61L27/3604 , A61L27/3808 , A61L27/3813 , A61L2430/40 , C12N1/04 , C12N2770/32634 , F25C1/142 , F26B5/065
摘要： A method for processing and preserving an acellular collagen-based tissue matrix for transplantation is disclosed. The method includes the steps of processing biological tissues with a stabilizing solution to reduce procurement damage, treatment with a processing solution to remove cells, treatment with a cryoprotectant solution followed by freezing, drying, storage and rehydration under conditions that preclude functionally significant damage and reconstitution with viable cells.

2. 发明申请

US20050159822A1 Particulate acellular tissue matrix 有权
标题翻译：颗粒无细胞组织基质
公开(公告)号：US20050159822A1
公开(公告)日：2005-07-21
申请号：US11040127
申请日：2005-01-20
申请人： Edward Griffey , Stephen Livesey , Charles Schiff , Lawrence Boerboom
发明人： Edward Griffey , Stephen Livesey , Charles Schiff , Lawrence Boerboom
IPC分类号： A61K9/00 , A61K9/19 , A61K35/12 , A61K35/28 , A61K35/32 , A61K35/36 , A61K38/18 , A61K47/42 , A61L27/24 , A61L27/36 , A61L27/38 , A61L31/00 , A61F2/02
CPC分类号： A61L27/3804 , A61K9/0024 , A61K9/19 , A61K35/28 , A61K35/32 , A61K35/36 , A61K38/18 , A61K47/42 , A61L27/24 , A61L27/3604 , A61L27/3683 , A61L31/005 , A61L2430/40 , Y10S514/801
摘要： A method of processing an acellular tissue matrix to give a particulate acellular tissue matrix includes: cutting sheets of dry acellular tissue matrix into strips; cryofracturing the dry acellular tissue matrix strips at cryogenic temperatures; separating the resulting particles by size at cryogenic temperatures; and freeze drying the fraction of particles desired size to remove any moisture that may have been absorbed to give a dry particulate acellular tissue matrix. Rehydration of the dry particulate acellular tissue matrix may take place just prior to use. The particulate acellular tissue may be applied to a recipient site, by way of injection, spraying, layering, packing, in-casing or combinations thereof. The particulate acelluar tissue may further include growth and stimulating agents selected from epidermal growth factor, fibroblast growth factor, nerve growth factor, keratinocyte growth factor, platelet derived growth factor, vasoactive intestinal peptide, stem cell factor, bone morphogetic proteins, chondrocyte growth factor and combinations thereof. Other pharmaceutically active compounds may be combined with the rehydrated particulate material including: analgesic drugs; hemostatic drugs; antibiotic drugs; local anesthetics and the like to enhance the acceptance of the implanted particulate material. The particulate material product may also be combined with stem cells selected from mesenchymal stem cells, epidermal stem cells, cartilage stem cells, hematopoietic stem cells and combinations thereof.
摘要翻译：一种处理无细胞组织基质以产生颗粒状无细胞组织基质的方法包括：将干燥的无细胞组织基质的片材切成条带; 在低温下对干燥的无细胞组织基质条进行冷冻干燥; 将所得颗粒在低温下分离大小; 并冷冻干燥所需尺寸的颗粒级分以除去可能被吸收的任何水分，以产生干燥的无细胞组织基质。干燥颗粒状无细胞组织基质的再水合可以在使用前进行。颗粒状脱细胞组织可以通过注射，喷雾，分层，包装，套管或其组合施用于受体部位。颗粒状细丝组织还可以包括生长和刺激剂，其选自表皮生长因子，成纤维细胞生长因子，神经生长因子，角质形成细胞生长因子，血小板衍生生长因子，血管活性肠肽，干细胞因子，骨形态蛋白，软骨细胞生长因子和其组合。其他药物活性化合物可以与再水合的颗粒材料组合，包括：止痛药; 止血药; 抗生素药物; 局部麻醉剂等，以增强植入颗粒物质的接受性。颗粒材料产品还可以与选自间充质干细胞，表皮干细胞，软骨干细胞，造血干细胞及其组合的干细胞组合。

3. 发明申请

US20070078522A2 Particulate Acellular Tissue Matrix 有权
标题翻译：颗粒无细胞组织矩阵
公开(公告)号：US20070078522A2
公开(公告)日：2007-04-05
申请号：US11040127
申请日：2005-01-20
申请人： Edward Griffey , Stephen Livesey , Charles Schiff , Lawrence Boerboom
发明人： Edward Griffey , Stephen Livesey , Charles Schiff , Lawrence Boerboom
IPC分类号： A61F2/02
CPC分类号： A61L27/3804 , A61K9/0024 , A61K9/19 , A61K35/28 , A61K35/32 , A61K35/36 , A61K38/18 , A61K47/42 , A61L27/24 , A61L27/3604 , A61L27/3683 , A61L31/005 , A61L2430/40 , Y10S514/801
摘要： A method of processing an acellular tissue matrix to give a particulate acellular tissue matrix includes: cutting sheets of dry acellular tissue matrix into strips; cryofracturing the dry acellular tissue matrix strips at cryogenic temperatures; separating the resulting particles by size at cryogenic temperatures; and freeze drying the fraction of particles desired size to remove any moisture that may have been absorbed to give a dry particulate acellular tissue matrix. Rehydration of the dry particulate acellular tissue matrix may take place just prior to use. The particulate acellular tissue may be applied to a recipient site, by way of injection, spraying, layering, packing, in-casing or combinations thereof. The particulate acellular tissue may further include growth and stimulating agents selected from epidermal growth factor, fibroblast growth factor, nerve growth factor, keratinocyte growth factor, platelet derived growth factor, vasoactive intestinal peptide, stem cell factor, bone morphogetic proteins, chondrocyte growth factor and combinations thereof. Other pharmaceutically active compounds may be combined with the rehydrated particulate material including: analgesic drugs; hemostatic drugs; antibiotic drugs; local anesthetics and the like to enhance the acceptance of the implanted particulate material. The particulate material product may also be combined with stem cells selected from mesenchymal stem cells, epidermal stem cells, cartilage stem cells, hematopoietic stem cells and combinations thereof.
摘要翻译：一种处理无细胞组织基质以产生颗粒状无细胞组织基质的方法包括：将干燥的无细胞组织基质的片材切成条带; 在低温下对干燥的无细胞组织基质条进行冷冻干燥; 将所得颗粒在低温下分离大小; 并冷冻干燥所需尺寸的颗粒级分以除去可能被吸收的任何水分，以产生干燥的无细胞组织基质。干燥颗粒状无细胞组织基质的再水合可以在使用前进行。颗粒状脱细胞组织可以通过注射，喷雾，分层，包装，套管或其组合施用于受体部位。颗粒细胞组织还可以包括生长和刺激剂，其选自表皮生长因子，成纤维细胞生长因子，神经生长因子，角质形成细胞生长因子，血小板衍生生长因子，血管活性肠肽，干细胞因子，骨形态蛋白，软骨细胞生长因子和其组合。其他药物活性化合物可以与再水合的颗粒材料组合，包括：止痛药; 止血药; 抗生素药物; 局部麻醉剂等，以增强植入颗粒物质的接受性。颗粒材料产品还可以与选自间充质干细胞，表皮干细胞，软骨干细胞，造血干细胞及其组合的干细胞组合。

4. 发明申请

US20050028228A1 Acellular tissue matrices made from alpa-1,3-galactose-deficient tissue 审中-公开
标题翻译：由alpa-1,3-半乳糖缺乏组织制成的无细胞组织基质
公开(公告)号：US20050028228A1
公开(公告)日：2005-02-03
申请号：US10896594
申请日：2004-07-21
申请人： David McQuillan , Edward Griffey , Herbert Beniker , Hui Xu
发明人： David McQuillan , Edward Griffey , Herbert Beniker , Hui Xu
IPC分类号： A01K67/027 , A01K67/033 , A01N63/00 , A61F2/02 , A61K48/00
CPC分类号： A61K35/32 , A61F2/0063 , A61K35/36 , A61K38/17 , A61K45/06 , A61L27/3604 , A61L27/3683 , A61L27/3695 , A61L2430/40 , C07K16/18 , C12N2533/92 , G01N33/6854 , A61K2300/00
摘要： The invention provides acellular tissue matrices made from collagen-containing tissues of animals genetically modified so as to be deficient in the galactose 1,3-galactose epitope and methods of making and using such acellular tissue matrices.
摘要翻译：本发明提供了由经过遗传修饰的动物的含胶原组织制成的缺乏半乳糖1,3-半乳糖表位的无细胞组织基质以及制备和使用这种无细胞组织基质的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式